← Back to Search

Dermal Filler

Belotero® Intense Lidocaine for Condition (BILUS Trial)

N/A
Waitlist Available
Research Sponsored by Merz North America, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) and week 8 post last injection, up to 12 weeks (v3)
Awards & highlights

BILUS Trial Summary

This trial studied the safety and effectiveness of a lip filler, Belotero Intense Lidocaine (BIL), to plump up thin lips.

BILUS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) and week 8 post last injection, up to 12 weeks (v3)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) and week 8 post last injection, up to 12 weeks (v3) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Change of Treated Lips From Baseline to Visit 3 (V3), According to the Merz Lip Fullness Assessment Scale (MLFAS)
Responder Rates at V3, According to the MLFAS
Secondary outcome measures
Change From Baseline in Rasch-transformed Score of the FACE-Q Satisfaction with Lips
Investigator's Global Aesthetic Improvement Scale (GAIS) Scores
Number of Subjects With Related Serious or Related Delayed-onset Treatment Emergent Adverse Events (TEAEs)
+1 more

Side effects data

From 2014 Phase 4 trial • 40 Patients • NCT01602692
40%
Nausea
10%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tumescent Solution With Dilute Epinephrine
Tumescent Solution With Dilute Lidocaine and Epinephrine

BILUS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Belotero® Intense LidocaineExperimental Treatment1 Intervention
Lips injected with BIL.
Group II: Restylane® SilkActive Control1 Intervention
Lips injected with RS.

Find a Location

Who is running the clinical trial?

Merz North America, Inc.Lead Sponsor
63 Previous Clinical Trials
8,802 Total Patients Enrolled
Merz Medical ExpertStudy DirectorMerz North America, Inc.
38 Previous Clinical Trials
7,107 Total Patients Enrolled

Media Library

Belotero Intense Lidocaine (Dermal Filler) Clinical Trial Eligibility Overview. Trial Name: NCT05773066 — N/A
Condition Research Study Groups: Restylane® Silk, Belotero® Intense Lidocaine
Condition Clinical Trial 2023: Belotero Intense Lidocaine Highlights & Side Effects. Trial Name: NCT05773066 — N/A
Belotero Intense Lidocaine (Dermal Filler) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05773066 — N/A
Condition Patient Testimony for trial: Trial Name: NCT05773066 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies available in this medical study?

"According to clinicaltrials.gov, this trial is actively seeking participants at present. The original post was made on March 3rd 2023 and the listing has been updated most recently on June 3rd 2023."

Answered by AI

Is this study seeking elderly volunteers aged 75 and above?

"According to the stated criteria, individuals between 21 and 65 years of age are eligible for this particular clinical trial."

Answered by AI

What are the qualifying criteria for taking part in this clinical trial?

"This clinical trial is accepting patients from 21 to 65 years old with lip fillers. In total, 220 participants are required for the study."

Answered by AI

What is the highest reported figure of participants in this experiment?

"Confirmed. According to the details hosted on clinicaltrials.gov, this medical experiment is currently enrolling participants and was first posted on March 3rd 2023 with an updated being published on March 6th 2023. It requires 220 individuals from 1 centre of care for completion."

Answered by AI

What is the intended outcome of this medical experiment?

"This clinical trial's primary outcome is the Responder Rates at V3, as evaluated through the MLFAS. Secondary outcomes include subjects' GAIS Scores, changes from Baseline in Rasch-transformed Score of the FACE-Q Satisfaction with Lips and Number of Subjects With Related Serious or Related Delayed-onset Treatment Emergent Adverse Events (TEAEs). These assessments span a period starting on Day 1 to Week 8 post last injection, up to 12 Weeks (V3)."

Answered by AI

Who else is applying?

What site did they apply to?
Merz Investigation Site #0010170
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Jus curious how good I good look.
PatientReceived 1 prior treatment

What questions have other patients asked about this trial?

How many sessions will this trial require?
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
[Trial of device that is not approved or cleared by the U.S. FDA]
2024. "[Trial of device that is not approved or cleared by the U.S. FDA]". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05773066.
~233 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top